Clinical Takeaway
Cannabis use for anxiety showed different daily and long-term effects depending on whether people used flower or edible products, and whether the product contained THC, CBD, or both. While CBD may support anxiety reduction, THC-dominant products carry the potential for variable or worsening anxiety outcomes, particularly with edibles where dosing is less predictable. Patients considering cannabis for anxiety should discuss product type, cannabinoid ratios, and delivery method with a knowledgeable clinician before use.
#8 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
Citation: Rosa Luiza et al.. Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.. International journal of environmental research and public health. 2026. PMID: 41752306.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This study addresses a critical gap in understanding cannabis’s real-world anxiolytic efficacy by documenting daily symptom changes in self-medicating patients, enabling clinicians to provide evidence-based counseling on product selection and expected outcomes. The finding that flower and edible products produce differential anxiolytic effects has direct implications for treatment recommendations, as it suggests formulation type may be as clinically relevant as cannabinoid composition alone. These longitudinal data are essential for informing clinical guidelines on cannabis use in anxiety disorders, where current treatment decisions rely heavily on anecdotal evidence rather than systematic outcome measurement.
Quality Gate Alerts:
- Preclinical only
Abstract: Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.
🧠 This study’s finding that edible cannabis products may produce more sustained anxiolytic effects than flower over 30 days is intriguing, yet several important limitations warrant cautious interpretation in clinical practice. The self-selected cohort of individuals motivated to use cannabis for anxiety introduces significant selection bias, and without biochemical confirmation of THC and CBD ratios across products, we cannot definitively attribute benefits to cannabinoid composition rather than user expectancy or unmeasured confounders like concurrent therapy or lifestyle changes. The ad libitum dosing protocol, while ecologically valid, obscures dose-response relationships and makes it difficult to identify optimal therapeutic windows or detect dose-dependent anxiety exacerbation, which THC can paradoxically produce in some individuals. For practitioners considering cannabis as an anxiety intervention, these results suggest that product formulation and delivery method may matter clinically, but emphasize the need for individualized titration, careful THC monitoring, structured follow-up, and concurrent evidence-based anxiety treatment rather than cannabis monotherapy.